Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Toxic epidermal necrolysis Indication Strategy Report 2026: Fas, Trials and Deals
3 August 2026
2026 Toxic epidermal necrolysis indication strategy covering epidemiology, Fas biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Oral chronic graft-versus-host disease Indication Strategy Report 2026: JAK, Trials and Deals
3 August 2026
2026 Oral chronic graft-versus-host disease indication strategy covering epidemiology, JAK biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Erosive oral lichen planus Indication Strategy Report 2026: JAK, Trials and Deals
3 August 2026
2026 Erosive oral lichen planus indication strategy covering epidemiology, JAK biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Lichen planus pemphigoides Indication Strategy Report 2026: IL-17, Trials and Deals
3 August 2026
2026 Lichen planus pemphigoides indication strategy covering epidemiology, IL-17 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Pretibial myxedema Indication Strategy Report 2026: IGF1R, Trials and Deals
3 August 2026
2026 Pretibial myxedema indication strategy covering epidemiology, IGF1R biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Nephrogenic systemic fibrosis Indication Strategy Report 2026: TGF-beta, Trials and Deals
3 August 2026
2026 Nephrogenic systemic fibrosis indication strategy covering epidemiology, TGF-beta biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Scleromyxedema Indication Strategy Report 2026: IL-6, Trials and Deals
3 August 2026
2026 Scleromyxedema indication strategy covering epidemiology, IL-6 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Calcinosis cutis universalis Indication Strategy Report 2026: Sodium thiosulfate, Trials and Deals
3 August 2026
2026 Calcinosis cutis universalis indication strategy covering epidemiology, Sodium thiosulfate biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Sneddon syndrome Indication Strategy Report 2026: C5, Trials and Deals
3 August 2026
2026 Sneddon syndrome indication strategy covering epidemiology, C5 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Degos disease Indication Strategy Report 2026: C5, Trials and Deals
3 August 2026
2026 Degos disease indication strategy covering epidemiology, C5 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Cutaneous polyarteritis nodosa Indication Strategy Report 2026: TNF, Trials and Deals
3 August 2026
2026 Cutaneous polyarteritis nodosa indication strategy covering epidemiology, TNF biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Necrobiotic xanthogranuloma Indication Strategy Report 2026: IL-6, Trials and Deals
3 August 2026
2026 Necrobiotic xanthogranuloma indication strategy covering epidemiology, IL-6 biology, active trials, transactions, unmet need, competition and market…